27884163|t|Chronic adiponectin deficiency leads to Alzheimer's disease -like cognitive impairments and pathologies through AMPK inactivation and cerebral insulin resistance in aged mice
27884163|a|Insulin resistance is the major pathogenesis underlying type 2 diabetes mellitus (T2DM) and these patients have doubled risk of Alzheimer's disease (AD). Increasing evidence suggests that insulin resistance plays an important role in AD pathogenesis, possibly due to abnormal GSK3β activation, causing intra- and extracellular amyloid-beta (Aβ) accumulation. Adiponectin (APN) is an adipokine with insulin-sensitizing and anti-inflammatory effects. Reduced circulatory APN level is associated with insulin resistance and T2DM. The role of APN in AD has not been elucidated. In this study, we aim to examine if adiponectin deficiency would lead to cerebral insulin resistance, cognitive decline and Alzheimer's-like pathology in mice. To study the role of adiponectin in cognitive functions, we employed adiponectin-knockout (APN-KO) mice and demonstrated chronic APN deficiency in their CNS. Behavioral tests were performed to study the cognitions of male APN-KO mice. Brains and tissue lysates were collected to study the pathophysiological and molecular changes in the brain of APN-KO mice. SH-SY5Y neuroblastoma cell line was used to study the molecular mechanism upon APN and insulin treatment. Aged APN -deficient mice displayed spatial memory and learning impairments, fear-conditioned memory deficit as well as anxiety. These mice also developed AD pathologies including increased cerebral Aβ42 level, Aβ deposition, hyperphosphorylated Tau proteins, microgliosis and astrogliosis with increased cerebral IL-1β and TNFα levels that associated with increased neuronal apoptosis and reduced synaptic proteins levels, suggesting APN deficiency may lead to neuronal and synaptic loss in the brain. AD pathologies -associated APN - KO mice displayed attenuated AMPK phosphorylation and impaired insulin signaling including decreased Akt induction and increased GSK3β activation in the hippocampus and frontal cortex. Aged APN -KO mice developed hippocampal insulin resistance with reduced pAkt induction upon intracerebral insulin injection. Consistently, APN treatment in SH-SY5Y cells with insulin resistance and overexpressing Aβ induce higher pAkt levels through AdipoR1 upon insulin treatment whereas the induction was blocked by compound C, indicating APN can enhance neuronal insulin sensitivity through AMPK activation. Our results indicated that chronic APN deficiency inactivated AMPK causing insulin desensitization and elicited AD-like pathogenesis in aged mice which also developed significant cognitive impairments and psychiatric symptoms.
27884163	8	30	adiponectin deficiency	T038	UMLS:C2675518
27884163	40	59	Alzheimer's disease	T038	UMLS:C0002395
27884163	66	87	cognitive impairments	T038	UMLS:C0338656
27884163	92	103	pathologies	T091	UMLS:C0030664
27884163	112	116	AMPK	T103	UMLS:C2350345
27884163	134	142	cerebral	T017	UMLS:C0006104
27884163	143	161	insulin resistance	T038	UMLS:C0021655
27884163	170	174	mice	T204	UMLS:C0026809
27884163	175	193	Insulin resistance	T038	UMLS:C0021655
27884163	207	219	pathogenesis	T038	UMLS:C0699748
27884163	231	255	type 2 diabetes mellitus	T038	UMLS:C0011860
27884163	257	261	T2DM	T038	UMLS:C0011860
27884163	303	322	Alzheimer's disease	T038	UMLS:C0002395
27884163	324	326	AD	T038	UMLS:C0002395
27884163	363	381	insulin resistance	T038	UMLS:C0021655
27884163	412	424	pathogenesis	T038	UMLS:C0699748
27884163	451	456	GSK3β	T103	UMLS:C0244989
27884163	457	467	activation	T038	UMLS:C0014429
27884163	477	483	intra-	T017	UMLS:C0175996
27884163	488	501	extracellular	T017	UMLS:C0521119
27884163	534	545	Adiponectin	T103	UMLS:C0389071
27884163	547	550	APN	T103	UMLS:C0389071
27884163	558	567	adipokine	T103	UMLS:C1955907
27884163	644	647	APN	T103	UMLS:C0389071
27884163	673	691	insulin resistance	T038	UMLS:C0021655
27884163	696	700	T2DM	T038	UMLS:C0011860
27884163	714	717	APN	T103	UMLS:C0389071
27884163	721	723	AD	T038	UMLS:C0002395
27884163	757	762	study	T062	UMLS:C2603343
27884163	785	807	adiponectin deficiency	T038	UMLS:C2675518
27884163	785	807	adiponectin deficiency	T038	UMLS:C2675518
27884163	822	830	cerebral	T017	UMLS:C0006104
27884163	831	849	insulin resistance	T038	UMLS:C0021655
27884163	851	868	cognitive decline	T038	UMLS:C0338656
27884163	873	899	Alzheimer's-like pathology	T038	UMLS:C0699748
27884163	903	907	mice	T204	UMLS:C0026809
27884163	912	917	study	T062	UMLS:C2603343
27884163	930	941	adiponectin	T103	UMLS:C0389071
27884163	945	964	cognitive functions	T038	UMLS:C0392335
27884163	978	998	adiponectin-knockout	T038	UMLS:C1522225
27884163	999	1012	(APN-KO) mice	T204	UMLS:C0206745
27884163	1038	1052	APN deficiency	T038	UMLS:C2675518
27884163	1062	1065	CNS	T022	UMLS:C3714787
27884163	1067	1083	Behavioral tests	T058	UMLS:C0683444
27884163	1102	1107	study	T062	UMLS:C2603343
27884163	1112	1122	cognitions	T038	UMLS:C0009240
27884163	1131	1142	APN-KO mice	T204	UMLS:C0206745
27884163	1144	1150	Brains	T017	UMLS:C0006104
27884163	1155	1161	tissue	T017	UMLS:C0040300
27884163	1188	1193	study	T062	UMLS:C2603343
27884163	1221	1238	molecular changes	T038	UMLS:C1148560
27884163	1246	1251	brain	T017	UMLS:C0006104
27884163	1255	1266	APN-KO mice	T204	UMLS:C0206745
27884163	1268	1299	SH-SY5Y neuroblastoma cell line	T017	UMLS:C0007600
27884163	1312	1317	study	T062	UMLS:C2603343
27884163	1322	1341	molecular mechanism	T038	UMLS:C3537153
27884163	1347	1350	APN	T103	UMLS:C0389071
27884163	1379	1382	APN	T103	UMLS:C0389071
27884163	1394	1398	mice	T204	UMLS:C0026809
27884163	1409	1423	spatial memory	T038	UMLS:C0814087
27884163	1428	1436	learning	T038	UMLS:C0023185
27884163	1437	1448	impairments	T038	UMLS:C0684336
27884163	1467	1481	memory deficit	T038	UMLS:C0233794
27884163	1493	1500	anxiety	T033	UMLS:C0003467
27884163	1508	1512	mice	T204	UMLS:C0026809
27884163	1528	1530	AD	T038	UMLS:C0002395
27884163	1531	1542	pathologies	T038	UMLS:C0699748
27884163	1563	1571	cerebral	T017	UMLS:C0006104
27884163	1572	1576	Aβ42	T103	UMLS:C0169424
27884163	1599	1631	hyperphosphorylated Tau proteins	T103	UMLS:C0085401
27884163	1633	1645	microgliosis	T038	UMLS:C3686874
27884163	1650	1662	astrogliosis	T038	UMLS:C0017639
27884163	1678	1686	cerebral	T017	UMLS:C0006104
27884163	1687	1692	IL-1β	T103	UMLS:C0021753
27884163	1697	1701	TNFα	T103	UMLS:C1456820
27884163	1740	1758	neuronal apoptosis	T038	UMLS:C1660771
27884163	1771	1779	synaptic	T082	UMLS:C0229984
27884163	1780	1795	proteins levels	T033	UMLS:C0428479
27884163	1808	1822	APN deficiency	T038	UMLS:C2675518
27884163	1869	1874	brain	T017	UMLS:C0006104
27884163	1876	1878	AD	T038	UMLS:C0002395
27884163	1903	1906	APN	T103	UMLS:C0389071
27884163	1909	1916	KO mice	T204	UMLS:C0206745
27884163	1938	1942	AMPK	T103	UMLS:C2350345
27884163	1943	1958	phosphorylation	T038	UMLS:C0031715
27884163	1972	1989	insulin signaling	T038	UMLS:C1512804
27884163	2010	2013	Akt	T103	UMLS:C0014442
27884163	2038	2043	GSK3β	T103	UMLS:C0244989
27884163	2044	2054	activation	T038	UMLS:C0014429
27884163	2062	2073	hippocampus	T017	UMLS:C0019564
27884163	2078	2092	frontal cortex	T017	UMLS:C0016733
27884163	2099	2102	APN	T103	UMLS:C0389071
27884163	2107	2111	mice	T204	UMLS:C0026809
27884163	2122	2133	hippocampal	T017	UMLS:C0019564
27884163	2134	2152	insulin resistance	T038	UMLS:C0021655
27884163	2166	2170	pAkt	T103	UMLS:C0014442
27884163	2200	2217	insulin injection	T058	UMLS:C0199782
27884163	2233	2236	APN	T103	UMLS:C0389071
27884163	2237	2246	treatment	T058	UMLS:C0087111
27884163	2269	2287	insulin resistance	T038	UMLS:C0021655
27884163	2292	2306	overexpressing	T038	UMLS:C1171362
27884163	2324	2328	pAkt	T103	UMLS:C0014442
27884163	2344	2351	AdipoR1	T103	UMLS:C1259440
27884163	2401	2408	blocked	T038	UMLS:C0028778
27884163	2412	2422	compound C	T103	UMLS:C1706082
27884163	2435	2438	APN	T103	UMLS:C0389071
27884163	2460	2479	insulin sensitivity	T038	UMLS:C0920563
27884163	2488	2492	AMPK	T103	UMLS:C2350345
27884163	2540	2554	APN deficiency	T038	UMLS:C2675518
27884163	2567	2571	AMPK	T103	UMLS:C2350345
27884163	2617	2637	AD-like pathogenesis	T038	UMLS:C0699748
27884163	2646	2650	mice	T204	UMLS:C0026809
27884163	2684	2705	cognitive impairments	T038	UMLS:C0338656
27884163	2710	2730	psychiatric symptoms	T033	UMLS:C0233401